Lars Dyrskjøt1, Molly A Ingersoll2,3. 1. Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Aarhus, Denmark. 2. Department of Immunology, Institut Pasteur. 3. INSERM U1223, Paris, France.
Abstract
PURPOSE OF REVIEW: Despite that nearly 75% of bladder cancer patients are diagnosed with nonmuscle-invasive disease, our understanding of the biological landscape in bladder cancer is primarily within the context of muscle-invasive bladder cancer. More recent studies addressing the genomic changes and immunology of nonmuscle-invasive bladder cancer (NMIBC) have helped to extend our understanding of this prevalent disease. RECENT FINDINGS: Genomic studies reveal that NMIBC possesses complexity that can be defined by specific gene expression signatures and has helped to define subsets within this disease. These subsets possess different risk profiles that may impact treatment decisions. In addition, the baseline or posttreatment immunological response to the growing tumor may help to inform whether a specific NMIBC subset is likely to progress. SUMMARY: Findings from studies addressing the molecular landscape of NMIBC may help to establish parameters for stratifying patient risk within this disease as well as establish novel or targeted treatment strategies. Inclusion of information about the immune response within tumors will likely contribute to defining the relative risk and treatment strategy for these patients.
PURPOSE OF REVIEW: Despite that nearly 75% of bladder cancerpatients are diagnosed with nonmuscle-invasive disease, our understanding of the biological landscape in bladder cancer is primarily within the context of muscle-invasive bladder cancer. More recent studies addressing the genomic changes and immunology of nonmuscle-invasive bladder cancer (NMIBC) have helped to extend our understanding of this prevalent disease. RECENT FINDINGS: Genomic studies reveal that NMIBC possesses complexity that can be defined by specific gene expression signatures and has helped to define subsets within this disease. These subsets possess different risk profiles that may impact treatment decisions. In addition, the baseline or posttreatment immunological response to the growing tumor may help to inform whether a specific NMIBC subset is likely to progress. SUMMARY: Findings from studies addressing the molecular landscape of NMIBC may help to establish parameters for stratifying patient risk within this disease as well as establish novel or targeted treatment strategies. Inclusion of information about the immune response within tumors will likely contribute to defining the relative risk and treatment strategy for these patients.
Authors: Sia Viborg Lindskrog; Frederik Prip; Philippe Lamy; Ann Taber; Clarice S Groeneveld; Karin Birkenkamp-Demtröder; Jørgen Bjerggaard Jensen; Trine Strandgaard; Iver Nordentoft; Emil Christensen; Mateo Sokac; Nicolai J Birkbak; Lasse Maretty; Gregers G Hermann; Astrid C Petersen; Veronika Weyerer; Marc-Oliver Grimm; Marcus Horstmann; Gottfrid Sjödahl; Mattias Höglund; Torben Steiniche; Karin Mogensen; Aurélien de Reyniès; Roman Nawroth; Brian Jordan; Xiaoqi Lin; Dejan Dragicevic; Douglas G Ward; Anshita Goel; Carolyn D Hurst; Jay D Raman; Joshua I Warrick; Ulrika Segersten; Danijel Sikic; Kim E M van Kessel; Tobias Maurer; Joshua J Meeks; David J DeGraff; Richard T Bryan; Margaret A Knowles; Tatjana Simic; Arndt Hartmann; Ellen C Zwarthoff; Per-Uno Malmström; Núria Malats; Francisco X Real; Lars Dyrskjøt Journal: Nat Commun Date: 2021-04-16 Impact factor: 17.694
Authors: Joshua J Meeks; Hikmat Al-Ahmadie; Bishoy M Faltas; John A Taylor; Thomas W Flaig; David J DeGraff; Emil Christensen; Benjamin L Woolbright; David J McConkey; Lars Dyrskjøt Journal: Nat Rev Urol Date: 2020-03-31 Impact factor: 14.432